胸腺肽α1联合左氧氟沙星治疗慢性阻塞性肺疾病急性加重期合并细菌性肺炎患者的效果

Effects of Thymosinα1 combined with Levofloxacin in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease complicated with bacterial pneumonia

目的:观察胸腺肽α1联合左氧氟沙星治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并细菌性肺炎患者的效果。方法:回顾性分析2021年1月至2023年1月该院收治的128例AECOPD合并细菌性肺炎患者的临床资料,按照治疗方法不同将其分为对照组和观察组各64例。两组均予以对症治疗,在此基础上,对照组予以左氧氟沙星治疗,观察组在对照组基础上联合胸腺肽α1治疗,两组均治疗2周。比较两组临床疗效,治疗前后肺功能指标[呼气流量峰值(PEF)、第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、FEV_(1)/FVC]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平、血清学指标[血清淀粉样蛋白A(SAA)、降钙素原(PCT)、细胞因子信号抑制因子3(SOCS3)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.31%(61/64),高于对照组的84.38%(54/64),差异有统计学意义(P<0.05);治疗后,观察组PEF、FEV_(1)、FVC、FEV_(1)/FVC、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组血清SAA、PCT、SOCS3水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:胸腺肽α1联合左氧氟沙星治疗AECOPD合并细菌性肺炎患者可提高治疗总有效率、肺功能指标水平和T细胞亚群指标水平,降低血清学指标水平,效果优于单纯左氧氟沙星治疗。

Objective:To observe effects of Thymosinα1 combined with Levofloxacin in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated with bacterial pneumonia.Methods:The clinical data of 128 patients with AECOPD complicated with bacterial pneumonia admitted to this hospital from January 2021 to January 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,64 cases in each.Both groups were given symptomatic treatment.On this basis,the control group was treated with Levofloxacin,while the observation group was treated with Thymosinα1 on the basis of that of the control group.Both groups were treated for 2 weeks.The clinical efficacy,the lung function indexes[peak expiratory flow(PEF),forced expiratory volume in one second(FEV_(1)),forced vital capacity(FVC),FEV_(1)/FVC]levels,the T cell subsets indexes(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))levels and the serological indexes[serum amyloid A(SAA),procalcitonin(PCT),cytokine signal inhibitor 3(SOCS3)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.31%(61/64),which was higher than 84.38%(54/64)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PEF,FEV_(1),FVC,FEV_(1)/FVC,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum SAA,PCT and SOCS3 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Thymosinα1 combined with Levofloxacin in the treatment of the AECOPD patients with bacterial pneumonia can improve the total effective rate,the lung function index levels and the T cell subset index levels,and reduce the levels of serological indexes.Moreover,it is superior to single Levofloxacin treatment.